Research programme: anticancer antibodies - BioInvent International/Cancer Research Technology

Drug Profile

Research programme: anticancer antibodies - BioInvent International/Cancer Research Technology

Latest Information Update: 18 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioInvent International; Cancer Research Technology; University of Southampton
  • Class Antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants; Macrophage inhibitors; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Dec 2015 BioInvent in-licenses technology to make efficacious immune stimulatory antibodies from the University of Southampton
  • 21 Apr 2015 BioInvent and Cancer Research Technology entered into collaboration with University of Southampton to co-develop antibodies for Cancer
  • 01 Apr 2015 Pharmacodynamics data from a preclinical trial in Cancer released by BioInvent
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top